Author: pr-moritz
Last saved by: Roland Birkhoff
Company: Bayer
Document comments: V-2024-03-05

Not intended for U.S. and UK Media
Radiological Society of North America (RSNA) 2024 Annual Meeting:
Bayer showcases innovations in radiology portfolio at RSNA 2024
•	New data for investigational MRI contrast agent gadoquatrane
•	Advancing collaboration with Subtle Medical to harness power of AI 
•	Introduction of Bayer’s latest CT injection system, MEDRAD™ Centargo, to the U.S.
•	Bayer’s Cortenic™ Connectivity Platform representing a growing connected ecosystem including software and services paired with smart injectors
•	Further Bayer tools for innovation in Radiology AI and digitalization and new collaborations in the area of AI to be presented

Sessions: S3A-SPNR-16, M7-SSNR06, M3-STCE2

Berlin, December 1, 2024 – Bayer continues to advance its comprehensive radiology portfolio with progress in the development pipeline as well as innovations in the area of Artificial Intelligence (AI). The company will present new data for gadoquatrane, Bayer’s investigational low dose macrocyclic gadolinium-based contrast agent currently in Phase III development, at the 2024 Radiological Society of North America (RSNA) Annual Meeting taking place from December 1-5, in Chicago, USA. 

On occasion of the congress, Bayer also announced to advance a collaboration with the global med tech company Subtle Medical. The joint goal is to harness the power of AI in medical imaging: The companies have agreed to move forward with the development of the investigational SubtleGAD™ deep-learning algorithm, with the goal to enable an investigational dose reduction of specific gadolinium-based contrast agents for patients undergoing contrast-enhanced MRI while maintaining diagnostic efficacy. 

Bayer will also present the latest addition to its CT product portfolio, the MEDRAD™ Centargo CT Injection System, which recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA). As one of the latest additions to its digital tools, Bayer will introduce its Cortenic™ Connectivity Platform at RSNA, which helps with creating smarter workflows based on data connectivity between injectors and individual systems within the radiology suite.

Further, Bayer will showcase at RSNA additional tools for innovation in Radiology AI and digitalization, from development to deployment: Its proprietary AI Innovation Platform (AIIP) aims to support development teams at healthcare organizations and startups from idea to launch of AI-enabled software solutions. Bayer is further advancing this offering by signing seven agreements with data providers. Bayer also introduced seven new collaboration agreements to expand the offering on its medical imaging platform Calantic™ Digital Solutions, which offers AI-enabled applications that are already available and cleared, orchestrated on one platform, for everyday clinical tasks.

The activities at RSNA reflect Bayer’s commitment as a leading company in key areas of radiology to unlock new opportunities and accelerate innovation for the benefit of patients while supporting radiologists and their teams in tackling current and future challenges.

New data for investigational contrast agent gadoquatrane – scientific paper awarded with the Kuo York Chynn Neuroradiology Research Award 

Gadoquatrane, Bayer’s investigational macrocyclic gadolinium-based contrast agent for MRI, is currently being investigated in Phase III studies to evaluate its potential to enable a substantially lower dose in patients undergoing contrast-enhanced MRI. There will be several scientific RSNA sessions about the compound.

Gadoquatrane: Pharmacokinetics in healthy volunteers and patients with CNS lesions in combination with MR imaging in comparison to gadobutrol support dose selection for the novel tetrameric GBCA
•	Session No. M7-SSNR06, Monday December 2, 3-4 pm CST, E450B
•	The purpose of the Phase I and II studies investigating gadoquatrane was to generate adequate data to facilitate dose selection for further development. Based on imaging and pharmacokinetic data, a dose of 0.04 mmol Gd/kg body weight was identified and is now being evaluated in a broad Phase III program.

The presentation will focus on highlights of a scientific paper which will be honored with the prestigious Kuo York Chynn Neuroradiology Research Award, being given for the top-rated Neuroradiology scientific paper for 2024. The award will be presented to the authors during the RSNA annual meeting.
		
Gadoquatrane: Dose-response assessment in MR angiography for the novel tetrameric macrocyclic GBCA in comparison to gadobutrol or gadoterate in a non-clinical and a clinical setting
•	Session No. S3A-SPNR, Sunday December 1, 11.45 am-12.15pm CST, Learning Center
•	The purpose of the investigations was to assess the signal enhancement properties of the tetrameric low dose macrocyclic GBCA gadoquatrane for the visualization of blood vessels (MR angiography) at different doses vs gadobutrol/gadoterate administered at the standard dose.

Determination of R1 relaxivities of gadobutrol and gadoquatrane at low and ultra-low magnetic field strengths
•	Session No. M3-STCE2, Monday December 2, 2024, 10-10.30 am CST, Learning Center Theatre 2
•	In a call for “cutting-edge research” abstracts by RSNA, this has been selected for the scientific session “low field and mobile MRI” 

Advancements in injection systems and technologies to be presented 

As a multi-patient system, Bayer’s MEDRAD™ Centargo CT Injection System enables radiology technologists to focus more on patient care and alleviates process and administrative burdens for healthcare providers, specifically in high throughput settings. Following EU CE marking in 2020, the product has already been launched in 49 markets to date and can now deliver value for radiology departments in the U.S. which are facing a shortage of radiology technologists coupled with a rising demand for medical imaging.

Connectivity-enabled offerings on Bayer’s Cortenic™ Connectivity Platform reflect the importance of data, connectivity, and interoperability in future healthcare and the opportunities they present across the continuum of care. 

Fostering digital innovation in Radiology 

Bayer is addressing key challenges when it comes to healthcare AI development: In April of this year, the company announced its collaboration with Google Cloud. Bayer’s new AI Innovation Platform (AIIP) is a cloud-based end-to-end software development platform designed to streamline and accelerate the development, validation, and deployment of imaging-based AI/ML (artificial intelligence/machine learning) healthcare applications, built on Google Cloud technology, which is in external testing. To broaden its offering on the AIIP, Bayer is announcing collaborations with external data providers OneMedNet, PhantomX, RadImageNet, Segmed, and Telepaxx Medical Data at RSNA. AIIP will also be supporting the multi-modal AI database "Deep Lake" from Activeloop, to make radiological data AI-ready and compatible with GenAI (generative AI) solutions and regular AI model training. Additionally, tools like RATify from Envisionit Deep AI will further contribute to the broad range of features available on AIIP and facilitate the creation, validation, research and real-world monitoring of AI imaging tools – supporting healthcare providers with high standards of accuracy and reliability in AI medical imaging, and in their compliance with the new EU AI Act and FDA guidelines.

Developed by radiologists for radiologists, Calantic™ Digital Solutions coordinates various third-party app solutions into a single convenient, cloud-based marketplace – vetted with Bayer's expertise, to ensure the feasibility and reliability of the apps offered. On the occasion of RSNA 2024, Bayer announced that it will partner with new radiology AI technology providers: Rad ai and AIRS Medical for its operational AI service line as well as Contextflow, Gleamer, AZmed, Smart Soft Healthcare, and Lucida Medical for its clinical service lines to further expand its offering on Calantic™ Digital Solutions. 
In addition, Blackford, an arm’s length company of Bayer, is presenting its Enterprise AI solutions. With its AI platform, tailored services, and a diverse portfolio of over 140 AI applications, they are designed to integrate smoothly into healthcare systems and to ensure seamless interoperability across imaging informatics workflows. 

In more than 40 thought leadership presentations at RSNA, Bayer’s medical, regulatory and product AI team members from Calantic™ Digital Solutions, Blackford, and other Bayer-related offerings will showcase insights to help healthcare providers, hospital administrators and developers advance their AI strategy, discussing topics like medical, regulatory, security, and compliance challenges in the field of AI in medical imaging, and how to bring AI-enabled healthcare solutions to market. 

About Bayer in Radiology 
As a true life-science company with a heritage of over 100 years in radiology, Bayer is committed to providing excellence – from innovative products to high-quality services – to support efficient and optimized patient care. Bayer offers a leading portfolio of contrast media for computed tomography (CT), X-ray, and magnetic resonance imaging (MRI), along with devices for their precise administration, informatics solutions, and a medical imaging platform delivering access to applications, including those enabled by AI. Bayer’s radiology products generated about €2bn sales in 2023.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to www.bayer.com.

Contact for media inquiries:
Simone Leyendecker, phone +49 174 9508190
Email: simone.leyendecker@bayer.com

Victoria Vigener, phone +49 151 23438911
Email: victoria.vigener@bayer.com 

Find more information at https://pharma.bayer.com/
Follow us on LinkedIn: Bayer | Pharmaceuticals
Follow us on Twitter: @BayerPharma

vvi	(2024-0182e)

Forward-Looking Statements 
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.